Are analysts optimistic about Oscar Health Inc.’s (NYSE:OSCR) stock?

Oscar Health Inc. (NYSE: OSCR) closed the day trading at 5.37 down -1.29% from the previous closing price of $5.44. In other words, the price has decreased by $-0.07 from its previous closing price. On the day, 1626571 shares were traded. OSCR reached its highest trading level at $5.59 during the session, while it also had its lowest trading level at $5.36.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.



For a better understanding of OSCR, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.50 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.04. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.24.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on June 15, 2022, Downgraded its rating to Underperform and sets its target price to $4.50 from $6 previously.

On May 26, 2022, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $12 to $6.

Goldman Downgraded its Neutral to Sell on February 14, 2022, whereas the target price for the stock was revised from $6.50 to $9.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 06 when Quane Alessandrea C. sold 17,532 shares for $5.53 per share. The transaction valued at 97,019 led to the insider holds 148,804 shares of the business.

Blackley Richard Scott sold 31,615 shares of OSCR for $174,951 on Sep 06. The Chief Financial Officer now owns 300,000 shares after completing the transaction at $5.53 per share. On Sep 02, another insider, Bopitiya Ranmali, who serves as the EVP & Chief Legal Officer of the company, sold 6,167 shares for $5.85 each. As a result, the insider received 36,077 and left with 28,721 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.41 while its Price-to-Book (P/B) ratio in mrq is 0.91.

Stock Price History:

Over the past 52 weeks, OSCR has reached a high of $18.89, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 6.09, while the 200-Day Moving Average is calculated to be 6.82.

Shares Statistics:

Over the past 3-months, OSCR traded about 1.91M shares per day on average, while over the past 10 days, OSCR traded about 2.46M shares per day. A total of 211.31M shares are outstanding, with a floating share count of 150.86M. Insiders hold about 0.50% of the company’s shares, while institutions hold 92.00% stake in the company. Shares short for OSCR as of Jul 14, 2022 were 10.32M with a Short Ratio of 4.11, compared to 8.55M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.89% and a Short% of Float of 9.52%.

Earnings Estimates

Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of $-0.48 for the current quarter, with a high estimate of $-0.19 and a low estimate of $-0.85, while EPS last year was $-0.35. The consensus estimate for the next quarter is $-0.7, with high estimates of $-0.59 and low estimates of $-0.83.

Analysts are recommending an EPS of between $-2.16 and $-2.73 for the fiscal current year, implying an average EPS of $-2.42. EPS for the following year is $-1.51, with 6 analysts recommending between $-1.29 and $-1.74.

Revenue Estimates

3 analysts predict $960.6M in revenue for the current quarter. It ranges from a high estimate of $993.25M to a low estimate of $916.54M. As of the current estimate, Oscar Health Inc.’s year-ago sales were $529.28M, an estimated increase of 81.50% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $949.9M, an increase of 129.30% over than the figure of $81.50% in the same quarter last year. There is a high estimate of $1.02B for the next quarter, whereas the lowest estimate is $895.66M.

A total of 5 analysts have provided revenue estimates for OSCR’s current fiscal year. The highest revenue estimate was $5.34B, while the lowest revenue estimate was $3.51B, resulting in an average revenue estimate of $4.05B. In the same quarter a year ago, actual revenue was $1.84B, up 120.40% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $4.59B in the next fiscal year. The high estimate is $4.8B and the low estimate is $4.3B. The average revenue growth estimate for next year is up 13.30% from the average revenue estimate for this year.